Literature DB >> 30722751

A case of late presentation of darunavir-related cholestatic hepatitis.

Nina Yancheva1, Radin Tzonev2.   

Abstract

We report a case of darunavir-induced cholestatic hepatitis in a human immunodeficiency virus (HIV)-infected patient in the third year of his combined antiretroviral therapy. During the patient's monthly follow-up with regard to his HIV infection, elevated transaminase levels were detected. The patient was subsequently hospitalised at the AIDS and gastroenterology departments. All tested viral hepatitis markers were negative. A diagnosis of autoimmune hepatitis was also ruled out. The liver biopsy revealed cholestatic hepatitis. Darunavir withdrawal resulted in a progressive decrease in liver enzyme levels. We highlight the importance of recognising late development of liver injury secondary to the use of darunavir, and the importance of monitoring liver function in patients undergoing prolonged treatment involving darunavir.

Entities:  

Keywords:  Darunavir; HIV; cholestatic hepatitis

Mesh:

Substances:

Year:  2019        PMID: 30722751     DOI: 10.1177/0956462419826723

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  5 in total

1.  The First Experience of Effective 3rd Line Antiretroviral Therapy - A Case of 40-Year-Old Female Retroviral-Infected Patient at Hawassa University Comprehensive Specialized Hospital, Hawassa, Sidama, Ethiopia.

Authors:  Worku Ketema; Kefyalew Taye; Mulugeta Sitot Shibeshi; Negash Tagesse; Agete Tadewos Hirigo; Kindie Woubishet; Selamawit Gutema; Aberash Eifa; Alemayehu Toma
Journal:  Res Rep Trop Med       Date:  2021-11-25

Review 2.  Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data.

Authors:  Ashley O Otto; Christina G Rivera; John D Zeuli; Zelalem Temesgen
Journal:  Cells       Date:  2021-05-20       Impact factor: 6.600

3.  Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database.

Authors:  Xiaojiang Tian; Yao Yao; Guanglin He; Yuntao Jia; Kejing Wang; Lin Chen
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379

4.  Clinical Features of COVID-19-Related Liver Functional Abnormality.

Authors:  Zhenyu Fan; Liping Chen; Jun Li; Xin Cheng; Jingmao Yang; Cheng Tian; Yajun Zhang; Shaoping Huang; Zhanju Liu; Jilin Cheng
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-10       Impact factor: 11.382

5.  Multicenter Analysis of Liver Injury Patterns and Mortality in COVID-19.

Authors:  Huikuan Chu; Tao Bai; Liuying Chen; Lilin Hu; Li Xiao; Lin Yao; Rui Zhu; Xiaohui Niu; Zhonglin Li; Lei Zhang; Chaoqun Han; Shuangning Song; Qi He; Ying Zhao; Qingjing Zhu; Hua Chen; Bernd Schnabl; Ling Yang; Xiaohua Hou
Journal:  Front Med (Lausanne)       Date:  2020-10-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.